AbbVie Statistics

Total Valuation

AbbVie has a market cap or net worth of CAD 537.64 billion. The enterprise value is 627.65 billion.

Market Cap	537.64B
Enterprise Value	627.65B

Important Dates

The next estimated earnings date is Friday, April 25, 2025.

Earnings Date	Apr 25, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.17%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.76B

Valuation Ratios

The trailing PE ratio is 88.17.

PE Ratio	88.17
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 16.41, with an EV/FCF ratio of 24.46.

EV / Earnings	102.93
EV / Sales	7.74
EV / EBITDA	16.41
EV / EBIT	24.46
EV / FCF	24.46

Financial Position

The company has a current ratio of 0.66, with a Debt / Equity ratio of 20.22.

Current Ratio	0.66
Quick Ratio	0.43
Debt / Equity	20.22
Debt / EBITDA	2.56
Debt / FCF	3.81
Interest Coverage	6.35

Financial Efficiency

Return on equity (ROE) is 62.29% and return on invested capital (ROIC) is 15.68%.

Return on Equity (ROE)	62.29%
Return on Assets (ROA)	8.25%
Return on Invested Capital (ROIC)	15.68%
Return on Capital Employed (ROCE)	18.49%
Revenue Per Employee	1.47M
Profits Per Employee	110,869
Employee Count	55,000
Asset Turnover	0.42
Inventory Turnover	4.04

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +14.23% in the last 52 weeks. The beta is 0.56, so AbbVie's price volatility has been lower than the market average.

Beta (5Y)	0.56
52-Week Price Change	+14.23%
50-Day Moving Average	26.52
200-Day Moving Average	26.40
Relative Strength Index (RSI)	78.43
Average Volume (20 Days)	15,655

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.28

Income Statement

In the last 12 months, AbbVie had revenue of CAD 81.06 billion and earned 6.10 billion in profits. Earnings per share was 3.44.

Revenue	81.06B
Gross Profit	56.99B
Operating Income	25.64B
Pretax Income	5.35B
Net Income	6.10B
EBITDA	37.71B
EBIT	25.64B
Earnings Per Share (EPS)	3.44

Full Income Statement

Balance Sheet

The company has 7.99 billion in cash and 97.87 billion in debt, giving a net cash position of -89.88 billion.

Cash & Cash Equivalents	7.99B
Total Debt	97.87B
Net Cash	-89.88B
Net Cash Per Share	n/a
Equity (Book Value)	4.84B
Book Value Per Share	2.71
Working Capital	-18.95B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 27.06 billion and capital expenditures -1.40 billion, giving a free cash flow of 25.66 billion.

Operating Cash Flow	27.06B
Capital Expenditures	-1.40B
Free Cash Flow	25.66B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 70.31%, with operating and profit margins of 31.64% and 7.59%.

Gross Margin	70.31%
Operating Margin	31.64%
Pretax Margin	6.60%
Profit Margin	7.59%
EBITDA Margin	46.52%
EBIT Margin	31.64%
FCF Margin	31.65%

Dividends & Yields

AbbVie does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	257.71%
Buyback Yield	-0.06%
Shareholder Yield	-0.06%
Earnings Yield	1.13%
FCF Yield	4.77%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AbbVie has an Altman Z-Score of 2.08. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.08
Piotroski F-Score	n/a